Serum Biomarker Based Algorithms in Diagnosis of Ovarian Cancer: A Review

Kumari, Suchitra

doi:10.1007/s12291-018-0786-2

Cited by 23 publications

(22 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, CHP-I could be a simpler method to optimize the management when assessing women with suspected OC, including age instead of menopausal status (11,17). (20,21). In the future, more research about these two indicators on different target groups to clarify these differences, aiming to overcome the limitations of these indicators and avail in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Copenhagen Index versus ROMA in the preoperative ovarian malignancy risk stratification: result from the first Vietnamese prospective cohort study

Tran

Lê

et al. 2021

Preprint

View full text Add to dashboard Cite

Objectives: This study aimed to evaluate the diagnostic performances of the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA) in the preoperative prediction of ovarian cancer.Methods: In a prospective cohort study, data were collected from 475 patients with ovarian masses who were hospitalized at the Departments of Obstetrics and Gynecology, Hue Central Hospital and Hue University of Medicine and Pharmacy Hospital, Vietnam, between January 2018 and June 2020. ROMA and CPH-I were included for the women who had measurements of serum carbohydrate antigen (CA-125) and human epididymis protein (HE4). Matching these values to postoperative histopathology resulted in the preoperative prediction values. The final diagnosis was based on clinical features, histologic, radiologic findings, and the International Federation of Gynecology and Obstetrics (FIGO) 2014 stages of ovarian cancer were recorded.Results: Among the 475 women, 408 had benign tumors, 5 had borderline tumors and 62 had malignant tumors. The two indices showed similar discriminatory performances with no significant differences (p > 0.05). At an optimal cut-off, the sensitivities/specificities of ROMA and CPH-I for ovarian cancer diagnosis were 76.1% and 87.0%, 83.6% and 78.7%, respectively. The optimal cut-off for CPH-I was 1.89%. The areas under the ROC curves (AUCs) of ROMA and CPH-I were 0.860 (95%CI: 0.825 – 0.890) and 0.868 (95%CI: 0.833 – 0.896), respectively.Conclusions: The introduction of the Copenhagen Index to help stratify the malignancy risk of ovarian tumor, irrespective of menopausal status might be applied as a simple alternative with a similar efficacy to ROMA in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Copenhagen Index versus ROMA in the preoperative ovarian malignancy risk stratification: result from the first Vietnamese prospective cohort study

Tran

Lê

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Nevertheless, a positive correlation between increased ccCK18 levels and treatment response was observed in this study and in several other (pre)clinical trials 60,77,78,81 . Therefore, the inclusion of ccCK18 in a biomarker panel (cancer antigen 125, human epididymis protein 4, e-cadherin,…) 83–85 in ovarian cancer therapy should not be neglected.…”

Section: Discussionmentioning

confidence: 99%

Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer

Clercq

Xie

Wever

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Patients with advanced ovarian cancer develop recurrence despite initial treatment response to standard treatment of surgery and intravenous/intraperitoneal (IP) chemotherapy, partly due to a limited peritoneal exposure time of chemotherapeutics. Paclitaxel-loaded genipin-crosslinked gelatin microspheres (PTX-GP-MS) are evaluated for the treatment of microscopic peritoneal carcinomatosis and prevention of recurrent disease. The highest drug load (39.2 µg PTX/mg MS) was obtained by immersion of GP-MS in aqueous PTX nanosuspension (PTXnano-GP-MS) instead of ethanolic PTX solution (PTXEtOH-GP-MS). PTX release from PTX-GP-MS was prolonged. PTXnano-GP-MS displayed a more controlled release compared to a biphasic release from PTXEtOH-GP-MS. Anticancer efficacy of IP PTX-GP-MS (PTXEtOH-GP-MS, D = 7.5 mg PTX/kg; PTXnano-GP-MS D = 7.5 and 35 mg PTX/kg), IP nanoparticular albumin-bound PTX (D = 35 mg PTX/kg) and controls (0.9% NaCl, blank GP-MS) was evaluated in a microscopic peritoneal carcinomatosis xenograft mouse model. PTXnano-GP-MS showed superior anticancer efficacy with significant increased survival time, decreased peritoneal carcinomatosis index score and ascites incidence. However, prolonged PTX release over 14 days from PTXnano-GP-MS caused drug-related toxicity in 27% of high-dosed PTXnano-GP-MS-treated mice. Dose simulations for PTXnano-GP-MS demonstrated an optimal survival without drug-induced toxicity in a range of 7.5–15 mg PTX/kg. Low-dosed PTXnano-GP-MS can be a promising IP drug delivery system to prevent recurrent ovarian cancer.

show abstract

“…OVERA uses HE4 and follicle-stimulating hormone (FSH) as replacements for B2-microglobulin and Transthyretin used in OVA1. OVA1 and OVERA have high sensitivities (92%, 94%) and low specificities (42%, 65%) [ 114 ].…”

Section: Early Detection Of Ovarian Cancermentioning

confidence: 99%

CA125 and Ovarian Cancer: A Comprehensive Review

Charkhchi

Cybulski

Gronwald

et al. 2020

Cancers

269

187

View full text Add to dashboard Cite

Ovarian cancer is the second most lethal gynecological malignancy. The tumour biomarker CA125 has been used as the primary ovarian cancer marker for the past four decades. The focus on diagnosing ovarian cancer in stages I and II using CA125 as a diagnostic biomarker has not improved patients’ survival. Therefore, screening average-risk asymptomatic women with CA125 is not recommended by any professional society. The dualistic model of ovarian cancer carcinogenesis suggests that type II tumours are responsible for the majority of ovarian cancer mortality. However, type II tumours are rarely diagnosed in stages I and II. The recent shift of focus to the diagnosis of low volume type II ovarian cancer in its early stages of evolution provides a new and valuable target for screening. Type II ovarian cancers are usually diagnosed in advanced stages and have significantly higher CA125 levels than type I tumours. The detection of low volume type II carcinomas in stage IIIa/b is associated with a higher likelihood for optimal cytoreduction, the most robust prognostic indicator for ovarian cancer patients. The diagnosis of type II ovarian cancer in the early substages of stage III with CA125 may be possible using a higher cutoff point rather than the traditionally used 35 U/mL through the use of point-of-care CA125 assays in primary care facilities. Rapid point-of-care testing also has the potential for effective longitudinal screening and quick monitoring of ovarian cancer patients during and after treatment. This review covers the role of CA125 in the diagnosis and management of ovarian cancer and explores novel and more effective screening strategies with CA125.

show abstract

Serum Biomarker Based Algorithms in Diagnosis of Ovarian Cancer: A Review

Cited by 23 publications

References 28 publications

Copenhagen Index versus ROMA in the preoperative ovarian malignancy risk stratification: result from the first Vietnamese prospective cohort study

Copenhagen Index versus ROMA in the preoperative ovarian malignancy risk stratification: result from the first Vietnamese prospective cohort study

Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer

CA125 and Ovarian Cancer: A Comprehensive Review

Contact Info

Product

Resources

About